Clene (CLNN) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Clene (CLNN) has outperformed Oncolytics Biotech (ONCY) over the past year, losing 62.0% versus a loss of 65.0%. Over five years, ONCY leads with a -80.7% price change compared with -96.3% for CLNN. Clene is the larger company by market cap ($50.7 million vs $47.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLNN | ONCY |
|---|---|---|
| Share price | $3.52 | $0.3501 |
| Market cap | $50.69M | $47.66M |
| 1-day change | +0.57% | -10.37% |
| YTD return | -40.03% | -59.76% |
| 1-year return | -62.03% | -64.99% |
| 5-year return | -96.28% | -80.66% |
| EPS (TTM) | $-2.30 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $200.00K | — |
| Revenue growth (YoY) | -41.52% | — |
| Net income (latest FY) | $-26.17M | $-28.76M |
| Gross margin | 78.50% | — |
| Operating margin | -11541.50% | — |
| Net margin | -13086.50% | — |
| 52-week high | $10.84 | $1.30 |
| 52-week low | $3.02 | $0.33 |
| Distance from 52-week high | -67.53% | -73.07% |
| Analyst consensus | none | buy |
| Avg. price target upside | +814.77% | +1085.38% |
| Average volume | 115.06K | 1.17M |
| Shares outstanding | 14.40M | 136.14M |
| Employees | 76 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
CLNN vs ONCY FAQ
Which is bigger, Clene or Oncolytics Biotech?
Clene (CLNN) is larger, with a market capitalization of $50.69M compared with $47.66M for Oncolytics Biotech (ONCY).
Which stock has performed better over the past year, CLNN or ONCY?
CLNN returned -62.03% over the past 12 months, compared with -64.99% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Clene and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.